Trials / Unknown
UnknownNCT02968472
A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
Single Center, Open, Phase I Clinical Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- The First People's Hospital of Yunnan · Academic / Other
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- Not accepted
Summary
A chimeric antigen receptor gene-modified T cells (CART: 4SCAR19)by targeted the CD19 (cluster of differentiation antigen 19), treat patients with CD19 positive malignant B cells tumor, assess treatment safety, and observe therapeutic effects. At the same time,the change process of the CART and residual tumor status of the patient are observe dynamically， which summarizes the best therapeutic effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | prophylactic 4SCAR19 cells | Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19 |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2019-05-01
- Completion
- 2019-05-01
- First posted
- 2016-11-18
- Last updated
- 2016-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02968472. Inclusion in this directory is not an endorsement.